The 2026 National Drug Control Strategy is out — and the contradictions are the story

The Office of National Drug Control Policy released the 2026 National Drug Control Strategy on May 4, framing the document as the policy roadmap for what the administration calls the “Great American Recovery Initiative.” The headline themes: more peer-support workers, more recovery-ready workplaces, more faith-based prevention and recovery partnerships, more “treatment for addiction to all types of drugs,” and — by ONDCP’s own fact sheet — strengthened overdose response including “increased naloxone availability and improved drug testing to guide treatment decisions.”

The phrase about drug testing matters, because it appears the same week SAMHSA’s April 24 letter pulled federal grant funding for fentanyl, xylazine, and medetomidine test strips, sterile syringes, sterile water, and overdose hotlines. That contradiction — public-health goals on the front of the document, restricted public-health funding behind it — is the story most clearly captured in News From The States’ coverage and in Filter Magazine’s analysis, which notes how heavily the strategy elevates concern about high-potency cannabis and intoxicating hemp-derived products.

What is in it that is genuinely new

Three pieces are worth tracking. The peer-support workforce build-out gives state and county recovery community organizations a federal mandate to expand certified peer-support programs and to integrate them into recovery-ready workplaces. The faith-based partnership emphasis gives recovery ministries — including the substantial Arizona faith-based recovery network — a clearer place at the table for settlement-fund applications and SAMHSA awards. The “treatment for all types of drugs” framing implicitly extends federal attention beyond opioids to stimulants, alcohol, and cannabis use disorder — reflecting the data, even if the policy implementation is uneven.

What is missing

The strategy does not name the funding mechanism for the harm-reduction inclusions it lists. It does not address the stimulant-treatment gap — 59% of recent overdose deaths involved a stimulant, and there are still no FDA-approved medications for stimulant-use disorder. And as the American Hospital Association noted in its May 6 brief, much of the strategy’s implementation will depend on appropriations — that is, on Congress, and on a SAMHSA whose grant restrictions are already on the books.

Why this matters for people in recovery

The new strategy is going to influence which programs get funded, which language gets used in MOUD encounters, and which counties build out peer-support and faith-based recovery services first. Families looking for help should know that the federal posture is changing without the on-the-ground supply changing as quickly. Locally distributed naloxone, peer-support pathways, and recovery-housing options remain available in Arizona today; the funding stream behind them is shifting. If you need help right now, SAMHSA’s National Helpline (1-800-662-HELP) is free and confidential, and Rize will keep mapping what is actually available, county by county, regardless of which pot of money is paying for it this quarter.